MariMed Reports Q1 2026 Financial Results

NORWOOD – MariMed Inc. turned in another quarter of measured progress in a tough Cannabis market. The company, with operations spanning cultivation, production, and retail facilities across multiple states, has reported year-over-year revenue growth and narrower losses, driven by gains in both retail and wholesale channels.

Revenue climbed to $39.5 million in Q1 2026, up from $37.9 million in the same period last year. Non-GAAP adjusted EBITDA rose to $3.6 million, or a 9% margin, compared with $2.5 million and 7% in the prior-year quarter. GAAP gross margin came in at 38.7%, while non-GAAP gross margin reached 40.1%, suggesting that unit economics held up despite ongoing price pressure across the industry.

Both retail and wholesale segments contributed to the growth. Management highlighted expanded wholesale distribution and the ongoing Expand the Brand strategy, which focuses on wider availability of MariMed’s core brands. In particular, Betty’s Eddies and Bubby’s Baked held the top spots in their respective edible categories in Massachusetts, and MariMed finished 2025 with product placement in 83% of dispensaries in that state.

The company pointed to disciplined operations and efficiency gains that helped support profitability. In March, MariMed announced a Restructuring and Exchange Agreement with holders of its $14.725 million Series B Convertible Preferred Stock, eliminating a February 26, 2026 mandatory conversion date and replacing it with longer-dated instruments. The deal extends the weighted average maturity of that obligation to 4.6 years, reducing near-term refinancing risk. For a company carrying an accumulated deficit of $131.7 million and total liabilities of $147.7 million, buying time on the debt clock is no small thing.

CEO Jon Levine said the results reflect continued execution in an environment where many operators face pricing pressure. He noted that the company remains focused on operational efficiency, brand strength, and positioning for longer-term opportunities, including potential benefits from Cannabis rescheduling. Looking ahead, MariMed has disclosed expansion plans in Ohio, New York, and Pennsylvania – markets that could meaningfully widen the revenue base if regulatory timelines cooperate. On the M&A front, Levine has added that accretive acquisitions remain a priority, though the company has been deliberate in avoiding deals that could strain the balance sheet.

MariMed’s Q1 numbers are credible rather than transformative. The company is doing what a disciplined operator should do. It’s trimming losses, protecting margins, and building brand equity in markets where it competes effectively. The restructured preferred stock was a necessary move, and the revenue beat against consensus adds a layer of credibility to management’s strategy. Still, an accumulated deficit north of $130 million and a sub-penny share price are not details to paper over. For MariMed, the path forward runs through Ohio, New York, Pennsylvania, and whatever federal policy changes ultimately produce.